Biomarker Strategy

MTX-101 development integrates biomarker identification at multiple levels:
- Target Expression
- Assessment of transporter expression via tumor biopsy or molecular profiling.
- Metabolic Flux Markers
- Evaluation of downstream metabolite signatures.
- Pharmacodynamic Markers
- Measurement of pathway suppression following dosing.

This biomarker-driven approach enables:
• Rational patient selection
• Early confirmation of target engagement
• Improved probability of clinical success